New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee

Jessica D. Daley; Susan L. Whiteway; Christine M. Heske; Filemon S. Dela Cruz; Sarah B. Whittle; Sarah Cohen-Gogo; Anderson B. Collier; Ajay Gupta; Joyce Ohm; Andrew Clark; Alice Soragni; Elizabeth Lawlor; Bhuvana Setty; Patrick J. Grohar; Katie Janeway; Damon R. Reed; Emily K. Slotkin; Kelly M. Bailey

doi:10.1002/pbc.31917

New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee

Jessica D. Daley, Susan L. Whiteway, Christine M. Heske, Filemon S. Dela Cruz, Sarah B. Whittle, Sarah Cohen-Gogo, Anderson B. Collier, Ajay Gupta, Joyce Ohm, Andrew Clark, Alice Soragni, Elizabeth Lawlor, Bhuvana Setty, Patrick J. Grohar, Katie Janeway, Damon R. Reed, Emily K. Slotkin, Kelly M. Bailey^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Outcomes for relapsed Ewing sarcoma remain consistently poor. Continued efforts to consider creative new approaches for the treatment of relapsed Ewing sarcoma are needed. The Children's Oncology Group Bone Tumor Committee convened a New Strategies for Ewing Sarcoma Task Force to systematically evaluate agents for inclusion in future Phase II or III clinical trials for relapsed Ewing sarcoma. In addition, the Task Force summarized the possible limitations of common trial designs and considered new approaches to study promising agents in clinical trials. Here, we summarize this work and propose next steps for future trials for relapsed Ewing sarcoma.

Original language	English
Article number	e31917
Journal	Pediatric Blood and Cancer
Volume	72
Issue number	10
DOIs	https://doi.org/10.1002/pbc.31917
State	Published - Oct 2025

Keywords

AYA
Ewing sarcoma
relapse

Access to Document

10.1002/pbc.31917

Cite this

Daley, J. D., Whiteway, S. L., Heske, C. M., Dela Cruz, F. S., Whittle, S. B., Cohen-Gogo, S., Collier, A. B., Gupta, A., Ohm, J., Clark, A., Soragni, A., Lawlor, E., Setty, B., Grohar, P. J., Janeway, K., Reed, D. R., Slotkin, E. K., & Bailey, K. M. (2025). New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee. Pediatric Blood and Cancer, 72(10), Article e31917. https://doi.org/10.1002/pbc.31917

@article{461162c26ff94750becbf0aee921e89b,

title = "New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee",

abstract = "Outcomes for relapsed Ewing sarcoma remain consistently poor. Continued efforts to consider creative new approaches for the treatment of relapsed Ewing sarcoma are needed. The Children's Oncology Group Bone Tumor Committee convened a New Strategies for Ewing Sarcoma Task Force to systematically evaluate agents for inclusion in future Phase II or III clinical trials for relapsed Ewing sarcoma. In addition, the Task Force summarized the possible limitations of common trial designs and considered new approaches to study promising agents in clinical trials. Here, we summarize this work and propose next steps for future trials for relapsed Ewing sarcoma.",

keywords = "AYA, Ewing sarcoma, relapse",

author = "Daley, {Jessica D.} and Whiteway, {Susan L.} and Heske, {Christine M.} and {Dela Cruz}, {Filemon S.} and Whittle, {Sarah B.} and Sarah Cohen-Gogo and Collier, {Anderson B.} and Ajay Gupta and Joyce Ohm and Andrew Clark and Alice Soragni and Elizabeth Lawlor and Bhuvana Setty and Grohar, {Patrick J.} and Katie Janeway and Reed, {Damon R.} and Slotkin, {Emily K.} and Bailey, {Kelly M.}",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC.",

year = "2025",

month = oct,

doi = "10.1002/pbc.31917",

language = "English",

volume = "72",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "10",

}

Daley, JD, Whiteway, SL, Heske, CM, Dela Cruz, FS, Whittle, SB, Cohen-Gogo, S, Collier, AB, Gupta, A, Ohm, J, Clark, A, Soragni, A, Lawlor, E, Setty, B, Grohar, PJ, Janeway, K, Reed, DR, Slotkin, EK & Bailey, KM 2025, 'New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee', Pediatric Blood and Cancer, vol. 72, no. 10, e31917. https://doi.org/10.1002/pbc.31917

TY - JOUR

T1 - New Approaches to Investigate Novel Agents in Ewing Sarcoma

T2 - A Report From the Children's Oncology Group Bone Tumor Committee

AU - Daley, Jessica D.

AU - Whiteway, Susan L.

AU - Heske, Christine M.

AU - Dela Cruz, Filemon S.

AU - Whittle, Sarah B.

AU - Cohen-Gogo, Sarah

AU - Collier, Anderson B.

AU - Gupta, Ajay

AU - Ohm, Joyce

AU - Clark, Andrew

AU - Soragni, Alice

AU - Lawlor, Elizabeth

AU - Setty, Bhuvana

AU - Grohar, Patrick J.

AU - Janeway, Katie

AU - Reed, Damon R.

AU - Slotkin, Emily K.

AU - Bailey, Kelly M.

PY - 2025/10

Y1 - 2025/10

N2 - Outcomes for relapsed Ewing sarcoma remain consistently poor. Continued efforts to consider creative new approaches for the treatment of relapsed Ewing sarcoma are needed. The Children's Oncology Group Bone Tumor Committee convened a New Strategies for Ewing Sarcoma Task Force to systematically evaluate agents for inclusion in future Phase II or III clinical trials for relapsed Ewing sarcoma. In addition, the Task Force summarized the possible limitations of common trial designs and considered new approaches to study promising agents in clinical trials. Here, we summarize this work and propose next steps for future trials for relapsed Ewing sarcoma.

AB - Outcomes for relapsed Ewing sarcoma remain consistently poor. Continued efforts to consider creative new approaches for the treatment of relapsed Ewing sarcoma are needed. The Children's Oncology Group Bone Tumor Committee convened a New Strategies for Ewing Sarcoma Task Force to systematically evaluate agents for inclusion in future Phase II or III clinical trials for relapsed Ewing sarcoma. In addition, the Task Force summarized the possible limitations of common trial designs and considered new approaches to study promising agents in clinical trials. Here, we summarize this work and propose next steps for future trials for relapsed Ewing sarcoma.

KW - AYA

KW - Ewing sarcoma

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=105011877736&partnerID=8YFLogxK

U2 - 10.1002/pbc.31917

DO - 10.1002/pbc.31917

M3 - Article

C2 - 40879325

AN - SCOPUS:105011877736

SN - 1545-5009

VL - 72

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 10

M1 - e31917

ER -